BioNTech SE
22UA
Company Profile
Business description
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
Contact
An der Goldgrube 12
MainzRPD-55131
DEUT: +49 613190840
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
6,772
Stocks News & Analysis
stocks
Our view on oil prices after Maduro is deposed
We’ve revisited our oil price assumptions after the news from Venezuela.
stocks
Nvidia: Full steam ahead with an impressive array of announcements at CES 2026
Our view of Nvidia at the current share price.
stocks
Cheapest ASX member of our Best Idea’s list
This share is trading at the lowest price to fair value of the 14 companies on the list.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,996.90 | 37.80 | -0.42% |
| CAC 40 | 8,237.43 | 25.93 | 0.32% |
| DAX 40 | 24,892.20 | 23.51 | 0.09% |
| Dow JONES (US) | 49,487.38 | 510.20 | 1.04% |
| FTSE 100 | 10,122.73 | 118.16 | 1.18% |
| HKSE | 26,710.45 | 363.21 | 1.38% |
| NASDAQ | 23,535.94 | 140.11 | 0.60% |
| Nikkei 225 | 52,518.08 | 685.28 | 1.32% |
| NZX 50 Index | 13,663.58 | 76.35 | 0.56% |
| S&P 500 | 6,945.67 | 43.62 | 0.63% |
| S&P/ASX 200 | 8,682.80 | 45.80 | -0.52% |
| SSE Composite Index | 4,083.67 | 60.25 | 1.50% |